Our efforts to promote the use of 1070nm intranasal and transcranial stimulation for prevention of COVID neuroinflammation has now been independently validated by this current report from Univ. of Queensland in Australia regarding changes in Microglial NLRP3 inflammasome activation. This response is associated with neurodegenerative disorders including Alzheimer's and Parkinson's disease and has been the focus of efforts by our collaborators at Durham University. This most recent finding is direct invitro evidence for how SARS COVID 2 virus causes the brain to become inflamed and 'angry' according to the authors Trent Woodruff and Eduardo Albornoz Balmaceda from the university’s School of Biomedical Sciences and virologists from the School of Chemistry and Molecular Biosciences. It was published in Nature’s Molecular Psychiatry.
The Neuradiant 1070nm transcranial photobiomodulation device can help reduce the inflammatory burden as we showed in our recent review article on the subject. (see attached)
We hope to see more efforts undertaken to show the value of light therapy as a way to quickly and safely protect ourselves from the neuroinflammatory damage that comes with COVID. More information at neuronic.online
Your comment will be posted after it is approved.
Leave a Reply.
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.